LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods ...
Simulations Plus' Q3 FY25 results missed expectations, with revenue guidance cut sharply due to biopharma market weakness and services segment volatility. Organic growth continues to decelerate and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback